Newer immunosuppressants in renal transplantation

Knechtle, 2004, Campath-1H in renal transplantation: the University of Wisconsin experience, Surgery, 136, 754, 10.1016/j.surg.2004.06.015 Hanaway, 2011, Alemtuzumab induction in renal transplantation, N Engl J Med, 364, 1909, 10.1056/NEJMoa1009546 Aspeslet, 2001, ISA(TX)247: a novel calcineurin inhibitor, Transplant Proc, 3, 1048, 10.1016/S0041-1345(00)02325-3 Stalder, 2003, In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates, J Heart Lung Transplant, 22, 1343, 10.1016/S1053-2498(03)00033-0 Changelian, 2003, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor, Science, 302, 875, 10.1126/science.1087061 Borie, 2005, Immunosuppression by the JAK3 inhibitor CP-690, 550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates, Transplantation, 79, 791, 10.1097/01.TP.0000157117.30290.6F Busque, 2007, CP-690,550, a JAK3 inhibitor, in de novo kidney transplant recipients: 6-month results of a phase 2 trial (abstract), Am J Transplant, 7, 304 Tan, 2003, Emerging and diverse roles of protein kinase C in immune cell signaling, Biochem J, 376, 545, 10.1042/bj20031406 Evenou, 2006, NVP-AEB071 (AEB), a novel protein kinase C inhibitor, abrogates early mouse T cell activation without affecting activation induced cell death (abstract), Am J Transplant, 6, 1029 Bruns, 2006, NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, Everolimus or FTY720 (abstract), Am J Transplant, 6, 316 Wagner, 2006, The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies (abstract), Am J Transplant, 6, 86 Bigaud, 2006, NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used a monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (abstract), Am J Transplant, 6, 250 Bigaud, 2006, NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C and early T-cell activation, prolongs non-human primates kidney allograft survival when combined with everolimus, ERL080 or FTY720 without calcineurin inhibitor (abstract), Am J Transplant, 6, 251 Vincenti, 2005, Chronic induction: what's new in the pipeline, 22 Larsen, 2005, Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties, Am J Transplant, 5, 443, 10.1111/j.1600-6143.2005.00749.x Vincenti, 2007, A phase I/II randomized openlabel multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation, Am J Transplant, 7, 1770, 10.1111/j.1600-6143.2007.01845.x Da Silva, 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and Cd2/Cd16-dependent apoptosis of CD2+ cells, J Immunol, 168, 4462, 10.4049/jimmunol.168.9.4462 Sayegh, 1998, The role of T-cell costimulatory activation pathways in transplant rejection, N Engl J Med, 338, 1813, 10.1056/NEJM199806183382506 Vincenti, 2008, Costimulation blockade in autoimmunity and transplantation, J Aller Clin Immunol, 121, 299, 10.1016/j.jaci.2008.01.002 Vincenti, 2005, Costimulation blockade with belatacept in renal transplantation, N Engl J Med, 353, 770, 10.1056/NEJMoa050085 Kirk, 1999, Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates, Nat Med, 5, 686, 10.1038/9536 Kirk, 2001, Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation (abstract), Am J Transplant, 1, 191 Aoyagi, 2007, A novel human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys, effect of induction and maintenance therapy (abstract #3), Am J Transplant, 7, 147 Nicolls, 2006, LFA-1 (CD11a) as a therapeutic target, Am J Transplant, 6, 27, 10.1111/j.1600-6143.2005.01158.x Posselt, 2008, Islet allograft survival in type 1 diabetics using a calcineurin-free protocol based on efalizumab and sirolimus (abstract #216), Am J Transplant, 8, 235 Krueger, 2003, Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis, Euro Acad Dermatol Verereol, 17, 17, 10.1046/j.1468-3083.17.s2.4.x Amersi, 2002, P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of Cd62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury, Am J Transplant, 2, 600, 10.1034/j.1600-6143.2002.20704.x Brown, 2006, Influence of donor C3 allotype on late renal-transplantation outcome, N Engl J Med, 354, 2014, 10.1056/NEJMoa052825 Wang, 2007, Inhibition of terminal complement components in presensitized transplant recipients prevents antibody mediated rejection leading to long-term graft survival and accommodation, J Immunol, 179, 4451, 10.4049/jimmunol.179.7.4451 Pescovitz, 2006, Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action, Am J Transplant, 6, 859, 10.1111/j.1600-6143.2006.01288.x Flint, 2011, Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression, Am J Transplant, 11, 1016, 10.1111/j.1600-6143.2011.03464.x Hideshima, 2010, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood, 1, 1530 Everly, 2008, Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection, Transplantation, 86, 1754, 10.1097/TP.0b013e318190af83